Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Karen Andreas
Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer
Oncologist
Cancer Research
Medicine
Oncology
Related publications
P1.13-36 Randomized Phase 2 Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
A Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients With Advanced EGFR Wild-Type Non-Small Cell Lung Cancer
BMC Research Notes
Biochemistry
Medicine
Genetics
Molecular Biology
P3.01-37 Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients With Wild-Type EGFR: TORG 1320
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Erlotinib Treatment in Pretreated Patients With Non-Small Cell Lung Cancer: A Phase II Study
Oncology Letters
Cancer Research
Oncology
Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib
Oncology Letters
Cancer Research
Oncology
Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients With Non–small Cell Lung Cancer: A Phase II Randomized Trial
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Phase I Trial of Sorafenib in Combination With Gefitinib in Patients With Refractory or Recurrent Non Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
